These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33787078)

  • 1. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
    Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
    Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
    Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW
    Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
    Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
    JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
    Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
    Beddowes E; Spicer J; Chan PY; Khadeir R; Corbacho JG; Repana D; Steele JP; Schmid P; Szyszko T; Cook G; Diaz M; Feng X; Johnston A; Thomson J; Sheaff M; Wu BW; Bomalaski J; Pacey S; Szlosarek PW
    J Clin Oncol; 2017 Jun; 35(16):1778-1785. PubMed ID: 28388291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
    Tsai HJ; Jiang SS; Hung WC; Borthakur G; Lin SF; Pemmaraju N; Jabbour E; Bomalaski JS; Chen YP; Hsiao HH; Wang MC; Kuo CY; Chang H; Yeh SP; Cortes J; Chen LT; Chen TY
    Sci Rep; 2017 Sep; 7(1):11253. PubMed ID: 28900115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
    Tomlinson BK; Thomson JA; Bomalaski JS; Diaz M; Akande T; Mahaffey N; Li T; Dutia MP; Kelly K; Gong IY; Semrad T; Gandara DR; Pan CX; Lara PN
    Clin Cancer Res; 2015 Jun; 21(11):2480-6. PubMed ID: 25739672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
    Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
    Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
    Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
    Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
    Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
    Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
    Tsimberidou AM; Keating MJ; Jabbour EJ; Ravandi-Kashani F; O'Brien S; Estey E; Bekele N; Plunkett WK; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):395-400.e1. PubMed ID: 24637132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Yao S; Janku F; Subbiah V; Stewart J; Patel SP; Kaseb A; Westin SN; Naing A; Tsimberidou AM; Hong D; Piha-Paul SA; Shi N; Johnston A; Bomalaski J; Fu S
    Br J Cancer; 2021 Apr; 124(9):1533-1539. PubMed ID: 33674736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
    Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
    Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
    Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
    J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
    Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.